82<strong>Update</strong> <strong>in</strong> <strong>Anaesthesia</strong>TRICHLOROETHYLENE (“Trilene”)Physical properties: Boils at 87 o C (high), SVP at 20 o C:60 mmHg. Blood/Gas partition coefficient: 9 (high), MAC0.17%Advantages: Non-irritant. Safe. Good analgesia dur<strong>in</strong>gand after surgery. Cardiovascularly stable. Very cheap,because one uses so little.Disadvantages: Low volatility, slow onset of effectbecause of high blood solubility and low boil<strong>in</strong>g po<strong>in</strong>tmak<strong>in</strong>g it impossible to get concentrations that are highenough. It is a potent agent because you need little toproduce an effect, BUT it is a weak anaesthetic because,despite this, vaporisers cannot produce high enoughconcentrations because the volatility is so low. Tachypnoeaused to be reported <strong>in</strong> the West but we don’t see it <strong>in</strong>Malawi. Dysrhythmias may occur with adrenal<strong>in</strong>e.Prolonged recovery, because of high blood solubility.Indications: analgesic supplement to halothane or usedon its own for m<strong>in</strong>or procedures such as fracturemanipulation, debridement etc.Contra<strong>in</strong>dications: overdosage <strong>in</strong> the elderly. Closedcircuit with soda-lime. Best avoided <strong>in</strong> very small babies.Dosage: 0.5 - 1% <strong>in</strong>itially, reduc<strong>in</strong>g to 0.2 - 0.5%.Practice Po<strong>in</strong>ts: Switch off 20-30 m<strong>in</strong>utes before theend of a long operation to avoid prolonged sedative effects.Its ideal function is to give background analgesia for longcases us<strong>in</strong>g halothane as the ma<strong>in</strong> anaesthetic but it is alsovery good given with halothane for a fast turn-over of shortcases us<strong>in</strong>g <strong>in</strong>halation <strong>in</strong>duction. We give it from a Goldmanhalothane vaporiser <strong>in</strong> series with a halothane vaporiser,us<strong>in</strong>g a gauze <strong>in</strong> the bowl to <strong>in</strong>crease evaporation. Thisgives about 0.7%.The newer agents:Enflurane: was a replacement for halothane, now used<strong>in</strong>frequently.Isoflurane: Boils at 48 o C. SVP at 20 o C: 250mmHg,Blood/Gas partition coefficient: 1.4, MAC: 1.15. Ingeneral use, good recovery because of relatively low bloodsolubility, but <strong>in</strong>duction difficult because of irritat<strong>in</strong>g badsmell, m<strong>in</strong>imal metabolism, no arrhythmias but causeshypotension, six times the cost of halothane. Big costreductions when used <strong>in</strong> a low flow system.Desflurane: Boils at 23.5 o C, SVP at 20 o C: 673 mmHg,Blood/Gas partition coefficient 0.4 (low), MAC: 5-10%.Replacement for enflurane, requires a specially designedvaporiser, has come and gone without me ever see<strong>in</strong>g it!Sevoflurane: Boils at 58.5 o C, SVP at 20 o C: 160 mmHg,Blood/Gas partition coefficient 0.6 (low), MAC: 1.7-2%.Fabulously expensive ($1000/litre), but costs can bereduced if used <strong>in</strong> a low flow system. There may beproblems with sevoflurane and carbon dioxide absorbers,baralyme <strong>in</strong> particular, but these are currently be<strong>in</strong>g<strong>in</strong>vestigated. Ultra low solubility result<strong>in</strong>g <strong>in</strong> ultra rapid<strong>in</strong>duction and recovery especially as it is non-irritant andsweet smell<strong>in</strong>g. High volatility and high percentage required.How should volatile agents be used?One way is to use them for <strong>in</strong>halation <strong>in</strong>duction ofanaesthesia followed by ma<strong>in</strong>tenance with the same oranother agent as your sole anaesthetic. The patient putshim or herself to sleep by breath<strong>in</strong>g via a close-fitt<strong>in</strong>g maskand provided the smell is accepted and the stage IIexcitement effects are not excessive, this is a verysatisfactory method of <strong>in</strong>duc<strong>in</strong>g general anaesthesia form<strong>in</strong>or cases without gastric aspiration risk. Lung disease,smok<strong>in</strong>g or dr<strong>in</strong>k<strong>in</strong>g habit, obesity and high uptakesituations (see above) will make this method slower andprolong stage II effects. Loss of airway <strong>in</strong> an obese patientmay be dangerous. Ideal for a fast turn-over of lots ofshort procedures on th<strong>in</strong> patients.The other way is to put up a drip and give an <strong>in</strong>travenous<strong>in</strong>duction followed by the volatile agent for ma<strong>in</strong>tenanceof anaesthesia. Very often the <strong>in</strong>travenous <strong>in</strong>duction will<strong>in</strong>clude <strong>in</strong>tubation of the trachea as well. All generalanaesthesia for major cases will be done this way.Further read<strong>in</strong>g1. Scurr C, Feldman S, Soni N. Scientific Foundations of<strong>Anaesthesia</strong>. Fourth Edition. Oxford: He<strong>in</strong>emann Medical Books19912. Fenton, P. M. Epidemiology of district surgery <strong>in</strong> Africa. Eastand Central African Journal of Surgery. 1997;3:33-41.
<strong>Update</strong> <strong>in</strong> <strong>Anaesthesia</strong> 83EXTRACTS FROM THE JOURNALSDr Henk Haisma, University Hospital Gron<strong>in</strong>gen, POBox 30001, 9700 RB Gron<strong>in</strong>gen, the Netherlandse-mail H.J.Haisma@anest.azg.nlPulmonary Artery Catheterization.Over the past decade, there has been vigorous debateconcern<strong>in</strong>g the <strong>in</strong>dication for, and cl<strong>in</strong>ical utility of, thePulmonary Artery Catheter (PAC). Recently, Connors etal.(1) reported an observational study of PAC useconducted <strong>in</strong> five teach<strong>in</strong>g hospitals <strong>in</strong> the United Statesbetween 1989 and 1994. In this study, the PAC wasassociated with both <strong>in</strong>creased mortality and utilisation ofresources when compared with case-matched controlpatients who did not undergo pulmonary arterycatheterisation. Despite the paper’s shortcom<strong>in</strong>gs (notprospective, nor randomised, nor a controlled trial) itserved as a catalyst to aga<strong>in</strong> <strong>in</strong>tensify heated debate overthe use of the PAC <strong>in</strong> the critically ill patient. Complicationsdirectly associated with the catheter itself does not seemto cause the problems but <strong>in</strong>correctly collectedhaemodynamic data may lead to improper therapeuticstrategies. Another factor is the documented significant<strong>in</strong>terobserver variability <strong>in</strong> <strong>in</strong>terpretation of pulmonary arterypressure trac<strong>in</strong>gs. Modification of care that PACs seemto provoke, like <strong>in</strong>creas<strong>in</strong>g the use of vasopressors,<strong>in</strong>otropes and <strong>in</strong>tensity of care, may, at times do moreharm than good. Also, disturb<strong>in</strong>g evidence exists suggest<strong>in</strong>gthat knowledge of basic pr<strong>in</strong>ciples of pulmonary arterycatheterization by physicians and nurses engaged <strong>in</strong> rout<strong>in</strong>euse of these devices is suboptimal.The study of Connors et al. led to a consensus conferencethat recommended guidel<strong>in</strong>es for the use of the PAC (2).Some of the f<strong>in</strong>al recommendations, which reflect thecollective op<strong>in</strong>ion of the participants, are: Cl<strong>in</strong>icians should cont<strong>in</strong>ue to carefully weigh therisks and benefits of the PAC.Cl<strong>in</strong>ician knowledge about the use of the PAC andits complications should be improved. The <strong>in</strong>dications and contra<strong>in</strong>dications for PAC use,where cl<strong>in</strong>ical evidence is lack<strong>in</strong>g, should bedeterm<strong>in</strong>ed.To summarise, most cl<strong>in</strong>icians believe that the PAC is useful<strong>in</strong> guid<strong>in</strong>g <strong>in</strong>travascular volume expansion andpharmacological <strong>in</strong>tervention <strong>in</strong> selected critically ill patients,however f<strong>in</strong>d<strong>in</strong>g clear evidence to substantiate this beliefis difficult, despite 25 years of PAC use!1. Connors Jr AF, Speroff T, Dawson NV, Thomas C, Harrell Jr FE,Wagner D, et al. The effectiveness of right heart catheterization<strong>in</strong> the <strong>in</strong>itial care of critically ill patients. JAMA 1996;276:889-8972. Pulmonary Artery Catheter Consensus Conference Participants.Pulmonary artery catheter consensus conference: consensusstatement. Crit Care Med 1997;25:910-925Management of Dural PunctureUn<strong>in</strong>tended dural punctures cont<strong>in</strong>ue to occur dur<strong>in</strong>g theattempted <strong>in</strong>sertion of epidural needles. Berger et al. (1)reported <strong>in</strong> a survey of 46 North American tertiary careobstetric centres on the management of dural puncturesoccurr<strong>in</strong>g with epidural analgesia dur<strong>in</strong>g labour. The<strong>in</strong>cidence of <strong>in</strong>advertant dural puncture was 0.4%-6%.Follow<strong>in</strong>g accidental dural puncture, 86% of patientsexperienced headache, <strong>in</strong> 63% of these patients it wassevere.Resit<strong>in</strong>g the epidural catheter at another level was the mostcommon <strong>in</strong>itial step (90%) after dural puncture. If anotherepidural catheter was successfully placed, most centresused their standard top up or <strong>in</strong>fusion regimes. Somecentres (ma<strong>in</strong>ly <strong>in</strong> the USA) considered cont<strong>in</strong>uous<strong>in</strong>trathecal catheters as an alternative if the epidural catheterproved difficult to place.Follow<strong>in</strong>g delivery 86% of centres allowed unrestrictedmobilisation. If headache occurred ly<strong>in</strong>g <strong>in</strong> bed was foundto be useful for pa<strong>in</strong> relief.Enhanced hydration, either orally or <strong>in</strong>travenously, to<strong>in</strong>crease CSF production, has not been shown to decreasethe risk of headache, but may lessen its severity. Thebeneficial effects of caffe<strong>in</strong>e are transient <strong>in</strong> many patients.17% of centres employed epidural sal<strong>in</strong>e boluses or<strong>in</strong>fusions.Prophylactic epidural blood patch (EBP) wasrecommended by 37% of centres, with twice as many USas Canadian centres do<strong>in</strong>g so. The EBP is still the mostefficacious treatment for a post dural puncture headachewith a reported success rate of greater than 90%. Theresolution of symptoms are thought to be caused by an<strong>in</strong>crease <strong>in</strong> CSF pressure from the <strong>in</strong>jection of an epiduralblood volume and formation of a clot at the site of thedural hole that seals and prevents further CSF leakage.1 Berger CW, Crosby ET, Groecki W. North American survey ofthe management of dural puncture occurr<strong>in</strong>g dur<strong>in</strong>g labourepidural analgesia. Can J Anaesth 1998; 45: <strong>11</strong>0-<strong>11</strong>4